DE602004015611D1 - Evaluierung adjuvanshaltiger impfstoffe - Google Patents

Evaluierung adjuvanshaltiger impfstoffe

Info

Publication number
DE602004015611D1
DE602004015611D1 DE602004015611T DE602004015611T DE602004015611D1 DE 602004015611 D1 DE602004015611 D1 DE 602004015611D1 DE 602004015611 T DE602004015611 T DE 602004015611T DE 602004015611 T DE602004015611 T DE 602004015611T DE 602004015611 D1 DE602004015611 D1 DE 602004015611D1
Authority
DE
Germany
Prior art keywords
antigen
solid phase
immunological activity
mixture
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004015611T
Other languages
English (en)
Inventor
Peter Adler Wuertzen
Gitte Lund
Henrik Hugo Jacobi
Hans-Henrik Ipsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALK Abello AS
Original Assignee
ALK Abello AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34276701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004015611(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ALK Abello AS filed Critical ALK Abello AS
Publication of DE602004015611D1 publication Critical patent/DE602004015611D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE602004015611T 2003-08-05 2004-07-28 Evaluierung adjuvanshaltiger impfstoffe Active DE602004015611D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49302003P 2003-08-05 2003-08-05
DKPA200301130 2003-08-05
PCT/DK2004/000514 WO2005022157A1 (en) 2003-08-05 2004-07-28 Evaluation of adjuvanted vaccines

Publications (1)

Publication Number Publication Date
DE602004015611D1 true DE602004015611D1 (de) 2008-09-18

Family

ID=34276701

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004015611T Active DE602004015611D1 (de) 2003-08-05 2004-07-28 Evaluierung adjuvanshaltiger impfstoffe

Country Status (13)

Country Link
EP (1) EP1649287B1 (de)
KR (1) KR101132439B1 (de)
CN (1) CN1829917B (de)
AT (1) ATE403867T1 (de)
AU (1) AU2004269076B2 (de)
CA (1) CA2532726C (de)
DE (1) DE602004015611D1 (de)
DK (1) DK1649287T3 (de)
ES (1) ES2310732T3 (de)
HK (1) HK1094036A1 (de)
MX (1) MXPA06001382A (de)
PL (1) PL1649287T3 (de)
WO (1) WO2005022157A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703903B2 (en) 2005-09-15 2014-04-22 Alk-Abello A/S Method for quantification of allergens
ES2349672T3 (es) * 2005-11-24 2011-01-10 Alk-Abello A/S Procedimiento para medir la actividad enzimática de enzima alergénica adsorbida.
AU2006317236B2 (en) * 2005-11-24 2012-01-19 Alk-Abello A/S A method of measuring enzymatic activity of adsorbed allergenic enzyme
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
ES2630029T3 (es) 2010-12-14 2017-08-17 Glaxosmithkline Biologicals Sa Análisis de citometría de flujo de materiales adsorbidos en sales metálicas
WO2013046226A2 (en) * 2011-08-04 2013-04-04 Serum Institute Of India Ltd. A novel quantification method for vaccines
CN109752560A (zh) * 2019-02-28 2019-05-14 艾棣维欣(苏州)生物制药有限公司 一种佐剂生物活性的检测方法
CN113009052A (zh) * 2021-02-22 2021-06-22 中国食品药品检定研究院 水痘减毒活疫苗中β-内酰胺类抗生素的检测方法
WO2023023164A1 (en) * 2021-08-17 2023-02-23 Innovar Scientific, Inc. Vaccine assessment and compliance testing methods and systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK140815B (da) * 1975-06-10 1979-11-19 Weeke Bengt Fremgangsmåde til påvisning eller bestemmelse af antistoffer i legemsvæsker ved hjælp af kendte antigener eller til bestemmelse af antigener ved hjælp af kendte antistoffer fra legemsvæsker samt et middel til anvendelse ved udøvelse af fremgangsmåden.
SU1746318A1 (ru) * 1990-06-05 1992-07-07 Институт полиомиелита и вирусных энцефалитов Способ определени концентрации белка Е вируса клещевого энцефалита в препаратах вакцины, сорбированных на гидроокиси алюмини
CN1276093C (zh) * 2001-05-15 2006-09-20 李卫云 一种检测丙肝病毒RdRp酶的方法，和载体以及用其转化的细胞株及应用

Also Published As

Publication number Publication date
ATE403867T1 (de) 2008-08-15
HK1094036A1 (en) 2007-03-16
KR20060126892A (ko) 2006-12-11
AU2004269076A1 (en) 2005-03-10
CN1829917B (zh) 2010-08-25
WO2005022157A1 (en) 2005-03-10
EP1649287A1 (de) 2006-04-26
DK1649287T3 (da) 2008-11-24
CA2532726C (en) 2013-03-12
ES2310732T3 (es) 2009-01-16
CN1829917A (zh) 2006-09-06
KR101132439B1 (ko) 2012-03-30
CA2532726A1 (en) 2005-03-10
MXPA06001382A (es) 2006-08-25
EP1649287B1 (de) 2008-08-06
PL1649287T3 (pl) 2009-04-30
AU2004269076B2 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
HK1094036A1 (en) Evaluation of adjuvanted vaccines
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
ATE188487T1 (de) Anti-gp39 antikoerper und deren verwendungen
WO2004055198A3 (en) Device and method for in-line blood testing using biochips
HUP0500444A2 (hu) HCV antigén/ellenanyag-kombinációs esszé
WO2006086561A3 (en) Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
AR094125A2 (es) Anticuerpo aislado anti il-12
DE602004031017D1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
DK1322960T3 (da) Allergen-mikroarrayassay
WO2005078450A3 (en) Method for the detection of early b cell populations in vaccine development
DE60331677D1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
WO2004073319A3 (en) Methods and compounds for raising antibodies and for screening antibody repertoires
WO2007005627A8 (en) Tuberculosis antigen detection assays and vaccines
DE60129278D1 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
PT1135158E (pt) Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica
ID20581A (id) Antigen rotavirus, vaksin dan agen diagnostik untuk infeksi rotavirus, serta metode untuk menghasilkan antigen
WO2003046140A3 (en) Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
ATE445839T1 (de) Latentes tuberkulose-diagnostisches antigen und verwendungsmethode
BR0011449A (pt) Método para detectar sìfilis usando antìgenos sintéticos
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
ATE420365T1 (de) Präparierung von sphären für diagnostische tests
Yu et al. Selection of SARS-coronavirus-specific B cell epitopes by phage peptide library screening and evaluation of the immunological effect of epitope-based peptides on mice

Legal Events

Date Code Title Description
8363 Opposition against the patent